Proactive Investors - Run By Investors For Investors

Tissue Regenix’s CellRight signs multi-year distribution agreement with Arthrex Inc.

The regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instruments and techniques to help influence better patient outcomes
X-Ray of knees
CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures

Tissue Regenix Group PLC (LON:TRX) shares jumped 6% higher on Tuesday as the firm announced that its subsidiary, CellRight Technologies has signed a long-term, multi-year distribution agreement with Arthrex Inc., a premier orthopaedic surgical solutions company.

The AIM-listed regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics - materials that help heal bone defects - and advanced surgical instruments and techniques to help influence better patient outcomes.

READ: Tissue Regenix launches new unit as it inks US distribution deal

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.

Steve Couldwell, Tissue Regenix's chief executive, commented: "This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space.”

Jesus Hernandez, chief executive of CellRight, added: "This long-term distribution agreement will allow physicians and patients better access to CellRight's innovative orthobiologics through the Arthrex network".

In late morning trading, Tissue Regenix shares were 6.1% higher at 8.75p.

 -- Adds share price --

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use